Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kantarjian, H. M.
Right arrow Articles by Freireich, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kantarjian, H. M.
Right arrow Articles by Freireich, E. J.
Journal of Clinical Oncology, Vol 18, Issue 3 (February), 2000: 547
© 2000 American Society for Clinical Oncology

Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

By Hagop M. Kantarjian, Susan O’Brien, Terry L. Smith, Jorge Cortes, Francis J. Giles, Miloslav Beran, Sherry Pierce, Yang Huh, Michael Andreeff, Charles Koller, Chul S. Ha, Michael J. Keating, Sharon Murphy, Emil J. Freireich

From the Departments of Leukemia, Biomathematics, and Radiotherapy, M.D. Anderson Cancer Center, Houston, TX; and Department of Hematology and Oncology, Children’s Memorial Hospital of Chicago, Chicago, IL.

Address reprint requests to Hagop M. Kantarjian, MD, Department of Leukemia, M.D. Anderson Cancer Center, Box 61, 1515 Holcombe Blvd, Houston, TX 77030.

PURPOSE: To evaluate the efficacy and toxicity of Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL).

PATIENTS AND METHODS: Adults with newly diagnosed ALL referred since 1992 were entered onto the study; treatment was initiated in 204 patients between 1992 and January 1998. No exclusions were made because of older age, poor performance status, organ dysfunction, or active infection. Median age was 39.5 years; 37% were at least 50 years old. Mature B-cell disease (Burkitt type) was present in 9%, T-cell disease in 17%. Leukocytosis of more than 30 x 109/L was found in 26%, Philadelphia chromosome–positive disease in 16% (20% of patients with assessable metaphases), CNS leukemia at the time of diagnosis in 7%, and a mediastinal mass in 7%. Treatment consisted of four cycles of Hyper-CVAD alternating with four cycles of high-dose methotrexate (MTX) and cytarabine therapy, together with intrathecal CNS prophylaxis and supportive care with antibiotic prophylaxis and granulocyte colony-stimulating factor therapy. Maintenance in patients with nonmature B-cell ALL included 2 years of treatment with mercaptopurine, MTX, vincristine, and prednisone (POMP).

RESULTS: Overall, 185 patients (91%) achieved complete remission (CR) and 12 (6%) died during induction therapy. Estimated 5-year survival and 5-year CR rates were 39% and 38%, respectively. The incidence of CNS relapse was low (4%). Compared with 222 patients treated with vincristine, doxorubicin, and dexamethasone (VAD) regimens, our patients had a better CR rate (91% v 75%, P < .01) and CR rate after one course (74% v 55%, P < .01) and better survival (P < .01), and a smaller percentage had more than 5% day 14 blasts (34% v 48%, P = .01). Previous prognostic models remained predictive for outcome with Hyper-CVAD therapy.

CONCLUSION: Hyper-CVAD therapy is superior to our previous regimens and should be compared with established regimens in adult ALL.




This article has been cited by other articles:


Home page
 haematolHome page
A. Usvasalo, R. Raty, S. Knuutila, K. Vettenranta, A. Harila-Saari, E. Jantunen, M. Kauppila, P. Koistinen, K. Parto, P. Riikonen, et al.
Acute lymphoblastic leukemia in adolescents and young adults in Finland
Haematologica, August 1, 2008; 93(8): 1161 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Pullarkat, M. L. Slovak, K. J. Kopecky, S. J. Forman, and F. R. Appelbaum
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study
Blood, March 1, 2008; 111(5): 2563 - 2572.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Rowe and A. H. Goldstone
How I treat acute lymphocytic leukemia in adults
Blood, October 1, 2007; 110(7): 2268 - 2275.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Pfeifer, B. Wassmann, A. Pavlova, L. Wunderle, J. Oldenburg, A. Binckebanck, T. Lange, A. Hochhaus, S. Wystub, P. Bruck, et al.
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Blood, July 15, 2007; 110(2): 727 - 734.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
A. Bleyer
Young Adult Oncology: The Patients and Their Survival Challenges
CA Cancer J Clin, July 1, 2007; 57(4): 242 - 255.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Jabbour, S. O'Brien, H. Kantarjian, G. Garcia-Manero, A. Ferrajoli, F. Ravandi, M. Cabanillas, and D. A. Thomas
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
Blood, April 15, 2007; 109(8): 3214 - 3218.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Douer, H. Yampolsky, L. J. Cohen, K. Watkins, A. M. Levine, A. P. Periclou, and V. I. Avramis
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia
Blood, April 1, 2007; 109(7): 2744 - 2750.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. de Labarthe, P. Rousselot, F. Huguet-Rigal, E. Delabesse, F. Witz, S. Maury, D. Rea, J.-M. Cayuela, M.-C. Vekemans, O. Reman, et al.
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study
Blood, February 15, 2007; 109(4): 1408 - 1413.
[Abstract] [Full Text] [PDF]

Home page
 ASH-SAPHome page
W. Stock and N. L. Seibel
Acute lymphoblastic leukemia and lymphoblastic lymphoma
ASH Self-Assessment Program, January 1, 2007; 2007(1): 253 - 264.
[Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
D. A. Thomas, H. M. Kantarjian, J. Cortes, S. Faderl, F. Giles, G. Garcia-Manero, W. Wierda, A. Ferrajoli, F. Ravandi-Kashani, S. Verstovsek, et al.
Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).
Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 284 - 284.
[Abstract] [PDF]

Home page
 BloodHome page
B. Wassmann, H. Pfeifer, N. Goekbuget, D. W. Beelen, J. Beck, M. Stelljes, M. Bornhauser, A. Reichle, J. Perz, R. Haas, et al.
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)
Blood, September 1, 2006; 108(5): 1469 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. M. Lazarus, S. M. Richards, R. Chopra, M. R. Litzow, A. K. Burnett, P. H. Wiernik, I. M. Franklin, M. S. Tallman, L. Cook, G. Buck, et al.
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993
Blood, July 15, 2006; 108(2): 465 - 472.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Bruggemann, T. Raff, T. Flohr, N. Gokbuget, M. Nakao, J. Droese, S. Luschen, C. Pott, M. Ritgen, U. Scheuring, et al.
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
Blood, February 1, 2006; 107(3): 1116 - 1123.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
N. Gokbuget and D. Hoelzer
Treatment of Adult Acute Lymphoblastic Leukemia
Hematology, January 1, 2006; 2006(1): 133 - 141.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
C.-H. Pui
Central Nervous System Disease in Acute Lymphoblastic Leukemia: Prophylaxis and Treatment
Hematology, January 1, 2006; 2006(1): 142 - 146.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Rowe, G. Buck, A. K. Burnett, R. Chopra, P. H. Wiernik, S. M. Richards, H. M. Lazarus, I. M. Franklin, M. R. Litzow, N. Ciobanu, et al.
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
Blood, December 1, 2005; 106(12): 3760 - 3767.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. Giles, G. Garcia-Manero, S. Kornblau, M. Andreeff, M. Beran, S. Verstovsek, et al.
Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1830 - 1830.
[Abstract]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
D. A. Thomas, J. Cortes, S. O'Brien, S. Faderl, F. Ravandi, G. Garcia-Manero, F. Giles, M. Beran, C. Koller, W. Wierda, et al.
Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1831 - 1831.
[Abstract]

Home page
 BloodHome page
W. N. Haining, D. S. Neuberg, H. L. Keczkemethy, J. W. Evans, S. Rivoli, R. Gelman, H. M. Rosenblatt, W. T. Shearer, J. Guenaga, D. C. Douek, et al.
Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia
Blood, September 1, 2005; 106(5): 1749 - 1754.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Bueso-Ramos, Y. Xu, T. J. McDonnell, S. Brisbay, S. Pierce, H. Kantarjian, G. Rosner, and G. Garcia-Manero
Protein Expression of a Triad of Frequently Methylated Genes, p73, p57Kip2, and p15, Has Prognostic Value in Adult Acute Lymphocytic Leukemia Independently of Its Methylation Status
J. Clin. Oncol., June 10, 2005; 23(17): 3932 - 3939.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Lee, Y.-J. Kim, C.-K. Min, H.-J. Kim, K.-S. Eom, D.-W. Kim, J.-W. Lee, W.-S. Min, and C.-C. Kim
The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Blood, May 1, 2005; 105(9): 3449 - 3457.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
O. G. Ottmann and B. Wassmann
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Hematology, January 1, 2005; 2005(1): 118 - 122.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
D. J. DeAngelo
The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Hematology, January 1, 2005; 2005(1): 123 - 130.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. A. Larson
Acute Lymphoblastic Leukemia: Older Patients and Newer Drugs
Hematology, January 1, 2005; 2005(1): 131 - 136.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. L. Ilaria Jr.
Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues
Hematology, January 1, 2005; 2005(1): 188 - 194.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
A. K. Mills, S. Gibbs, C. Keane, P. Mollee, K. Grimmett, R. Van Kuilenburg, R. Saal, D. Gill, H. M. Prince, J. F. Seymour, et al.
Optimal Timing of Peripheral Blood Stem Cell Mobilisation in Patients with Hematological Malignancies Treated with the Hyper-CVAD Chemotherapy Regimen.
Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 5213 - 5213.
[Abstract]

Home page
 BloodHome page
M. Hunault, J.-L. Harousseau, M. Delain, M. Truchan-Graczyk, J.-Y. Cahn, F. Witz, T. Lamy, B. Pignon, J.-P. Jouet, R. Garidi, et al.
Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial
Blood, November 15, 2004; 104(10): 3028 - 3037.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
X. Thomas, J.-M. Boiron, F. Huguet, H. Dombret, K. Bradstock, N. Vey, T. Kovacsovics, A. Delannoy, N. Fegueux, P. Fenaux, et al.
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
J. Clin. Oncol., October 15, 2004; 22(20): 4075 - 4086.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. A. Thomas, S. O'Brien, J. Cortes, F. J. Giles, S. Faderl, S. Verstovsek, A. Ferrajoli, C. Koller, M. Beran, S. Pierce, et al.
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
Blood, September 15, 2004; 104(6): 1624 - 1630.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. G. Kiehl, L. Kraut, R. Schwerdtfeger, B. Hertenstein, M. Remberger, N. Kroeger, M. Stelljes, M. Bornhaeuser, H. Martin, C. Scheid, et al.
Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission
J. Clin. Oncol., July 15, 2004; 22(14): 2816 - 2825.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. J. Giles, S. M. Kornblau, G. Garcia-Manero, M. J. Keating, M. Andreeff, S. Jeha, et al.
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Blood, June 15, 2004; 103(12): 4396 - 4407.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
K. K. Ballen and R. P. Hasserjian
Case 15-2004 - A 31-Year-Old Man with Bilateral Testicular Enlargement
N. Engl. J. Med., May 13, 2004; 350(20): 2081 - 2087.
[Full Text] [PDF]

Home page
 NEJMHome page
C.-H. Pui, M. V. Relling, and J. R. Downing
Acute Lymphoblastic Leukemia
N. Engl. J. Med., April 8, 2004; 350(15): 1535 - 1548.
[Full Text] [PDF]

Home page
 BloodHome page
S. Lee, D.-W. Kim, Y.-J. Kim, N.-G. Chung, Y.-L. Kim, J.-Y. Hwang, and C.-C. Kim
Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia
Blood, October 15, 2003; 102(8): 3068 - 3070.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Shen, M. Toyota, Y. Kondo, T. Obata, S. Daniel, S. Pierce, K. Imai, H. M. Kantarjian, J.-P. J. Issa, and G. Garcia-Manero
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia
Blood, May 15, 2003; 101(10): 4131 - 4136.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
A. L. Nashed, K. W. Rao, and M. L. Gulley
Clinical Applications of BCR-ABL Molecular Testing in Acute Leukemia
J. Mol. Diagn., May 1, 2003; 5(2): 63 - 72.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Boissel, M.-F. Auclerc, V. Lheritier, Y. Perel, X. Thomas, T. Leblanc, P. Rousselot, J.-M. Cayuela, J. Gabert, N. Fegueux, et al.
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
J. Clin. Oncol., March 1, 2003; 21(5): 774 - 780.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E.-F. Solomayer, M. Feuerer, L. Bai, V. Umansky, P. Beckhove, G. C. Meyberg, G. Bastert, V. Schirrmacher, and I. J. Diel
Influence of Adjuvant Hormone Therapy and Chemotherapy on the Immune System Analysed in the Bone Marrow of Patients with Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 174 - 180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Karp, D. D. Ross, W. Yang, M. L. Tidwell, Y. Wei, J. Greer, D. L. Mann, T. Nakanishi, J. J. Wright, and A. D. Colevas
Timed Sequential Therapy of Acute Leukemia with Flavopiridol: In Vitro Model for a Phase I Clinical Trial
Clin. Cancer Res., January 1, 2003; 9(1): 307 - 315.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. G. Ottmann, B. J. Druker, C. L. Sawyers, J. M. Goldman, J. Reiffers, R. T. Silver, S. Tura, T. Fischer, M. W. Deininger, C. A. Schiffer, et al.
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
Blood, August 28, 2002; 100(6): 1965 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Powles, B. Sirohi, J. Treleaven, S. Kulkarni, D. Tait, S. Singhal, and J. Mehta
The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia
Blood, August 13, 2002; 100(5): 1641 - 1647.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Garcia-Manero, J. Daniel, T. L. Smith, S. M. Kornblau, M.-S. Lee, H. M. Kantarjian, and J.-P. J. Issa
DNA Methylation of Multiple Promoter-associated CpG Islands in Adult Acute Lymphocytic Leukemia
Clin. Cancer Res., July 1, 2002; 8(7): 2217 - 2224.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Garcia-Manero, C. Bueso-Ramos, J. Daniel, J. Williamson, H. M. Kantarjian, and J.-P. J. Issa
DNA Methylation Patterns at Relapse in Adult Acute Lymphocytic Leukemia
Clin. Cancer Res., June 1, 2002; 8(6): 1897 - 1903.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Linker, L. Damon, C. Ries, and W. Navarro
Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic Leukemia
J. Clin. Oncol., May 15, 2002; 20(10): 2464 - 2471.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Glei{beta}ner, N. Gokbuget, C. R. Bartram, B. Janssen, H. Rieder, J. W. G. Janssen, C. Fonatsch, A. Heyll, D. Voliotis, J. Beck, et al.
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis
Blood, March 1, 2002; 99(5): 1536 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. J. Giles, G. Garcia-Manero, J. E. Cortes, S. D. Baker, C. B. Miller, S. M. O'Brien, D. A. Thomas, M. Andreeff, C. Bivins, J. Jolivet, et al.
Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia
J. Clin. Oncol., February 1, 2002; 20(3): 656 - 664.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Annino, M. L. Vegna, A. Camera, G. Specchia, G. Visani, G. Fioritoni, F. Ferrara, A. Peta, S. Ciolli, W. Deplano, et al.
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study
Blood, February 1, 2002; 99(3): 863 - 871.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski
Acute Lymphoblastic Leukemia
Hematology, January 1, 2002; 2002(1): 162 - 192.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
A. Lister, L. E. Abrey, and J. T. Sandlund
Central Nervous System Lymphoma
Hematology, January 1, 2002; 2002(1): 283 - 296.
[Abstract] [Full Text]

Home page
 BloodHome page
J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
Blood, June 1, 2001; 97(11): 3361 - 3369.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Srivannaboon, A. B. Shanafelt, E. Todisco, C. P. Forte, F. G. Behm, S. C. Raimondi, C.-H. Pui, and D. Campana
Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells
Blood, February 1, 2001; 97(3): 752 - 758.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online